-
平臺編號：bio-68103
-
國際編號：CRL-2003?
-
細胞信息： TF-1
-
規(guī)格：frozen
-
用途：ATCC原裝細胞
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
TF-1
器官來源：骨髓
ATCC Number：CRL-2003?
運輸方式：凍存運輸
相關(guān)疾病：白血病
細胞形態(tài)：淋巴樣
細胞類型：其他細胞類型
是否是腫瘤細胞：0
物種來源：人
生長狀態(tài)：懸浮生長
年限：35 years
數(shù)量：大量
規(guī)格：0.5mg Designations: TF-1
Depositors: ?T Kitamura
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: bone marrow
Disease: erythroleukemia
Cell Type: erythroblast
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications:transfection host (Roche Transfection Reagents )
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 13,14
D13S317: 8,9
D16S539: 9,12
D5S818: 13
D7S820: 12
THO1: 7,9
TPOX: 8
vWA: 15,17
Age: 35 years
Gender: male
Ethnicity: Japanese
Comments:The TF-1 cell line was established by T. Kitamura, et al. in October 1987 from a heparinized bone marrow aspiration sample from a 35 year old Japanese male with severe pancytopenia.The cells are completely dependent on interleukin 3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) for long term growth. The cells DO NOT RESPOND to interleukin 5 (IL-5).TF-1 cells respond to a variety of other lymphokines and cytokines such as interleukin 1 (IL-1), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 9 (IL-9),Interleukin 11 (IL-11), interleukin 13 (IL-13), stem cell factor (SCF), leukemia inhibitory factor (LIF) and nerve growth factor (NGF).TF-1 cells do not express glycophorin A or carbonyl anhydrase I.The morphological and cytochemical features, and the constitutive expression of globin genes, indicate the commitment of the cells to the erythroid lineage. Hemin and delta-aminolevulinic acid induce hemoglobin synthesis, and TPA induces dramatic differentiation of the TF-1 cells into macrophage-like cells. The TF-1 cell line is unique because of its responsiveness to multiple cytokines and provides a good system for investigating the proliferation and differentiation of myeloid progenitor cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 2 ng/ml recombinant human GM-CSF; fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10(4) viable cells/ml. Do not allow the cell concentration to reach 7 X 10(5) cells/ml.
Interval: Maintain cultures between 3 X 10(4) and 5 X 10(5) viable cells/ml
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 22 hours
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
derivative:ATCC CRL-2451
derivative:ATCC CRL-2512
References: 22415: Kitamura T, et al. IL-1 up-regulates the expression of cytokine receptors on a factor- dependent human hemopoietic cell line, TF-1. Int. Immunol. 3: 571-577, 1991. PubMed: 1832294
22619: Kitamura T, et al. Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood 73: 375-380, 1989. PubMed: 2537111
23007: Kitamura T, et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 140: 323-334, 1989. PubMed: 2663885
23415: Borellini F, Glazer RI. Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J. Biol. Chem. 268: 7923-7928, 1993. PubMed: 8463313
30089: Schulte T, et al. Molecular characterization and functional analysis of murine interleukin 4 receptor allotypes. J. Exp. Med. 186: 1419-1429, 1997. PubMed: 9348299
30146: Mueller CG, et al. Polymerase chain reaction selects a novel disintegrin proteinase from CD40-activated germinal center dendritic cells. J. Exp. Med. 186: 655-663, 1997. PubMed: 9271581
30515: Limon A, et al. High-titer retroviral vectors containing the enhanced green fluorescent protein gene for efficient expression in hematopoietic cells. Blood 90: 3316-3321, 1997. PubMed: 9345013
49300: Hu X, et al. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. Cell Growth Differ. 11: 191-200, 2000. PubMed: 10775036
92234: USP Monographs: Sargramostim. Rockville, MD: U.S. Pharmacopeia; USP USP34-NF29, 2011
ATCC Number：CRL-2003?
運輸方式：凍存運輸
相關(guān)疾病：白血病
細胞形態(tài)：淋巴樣
細胞類型：其他細胞類型
是否是腫瘤細胞：0
物種來源：人
生長狀態(tài)：懸浮生長
年限：35 years
數(shù)量：大量
規(guī)格：0.5mg Designations: TF-1
Depositors: ?T Kitamura
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: bone marrow
Disease: erythroleukemia
Cell Type: erythroblast
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Applications:transfection host (Roche Transfection Reagents )
DNA Profile (STR):Amelogenin: X,Y
CSF1PO: 13,14
D13S317: 8,9
D16S539: 9,12
D5S818: 13
D7S820: 12
THO1: 7,9
TPOX: 8
vWA: 15,17
Age: 35 years
Gender: male
Ethnicity: Japanese
Comments:The TF-1 cell line was established by T. Kitamura, et al. in October 1987 from a heparinized bone marrow aspiration sample from a 35 year old Japanese male with severe pancytopenia.The cells are completely dependent on interleukin 3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) for long term growth. The cells DO NOT RESPOND to interleukin 5 (IL-5).TF-1 cells respond to a variety of other lymphokines and cytokines such as interleukin 1 (IL-1), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 9 (IL-9),Interleukin 11 (IL-11), interleukin 13 (IL-13), stem cell factor (SCF), leukemia inhibitory factor (LIF) and nerve growth factor (NGF).TF-1 cells do not express glycophorin A or carbonyl anhydrase I.The morphological and cytochemical features, and the constitutive expression of globin genes, indicate the commitment of the cells to the erythroid lineage. Hemin and delta-aminolevulinic acid induce hemoglobin synthesis, and TPA induces dramatic differentiation of the TF-1 cells into macrophage-like cells. The TF-1 cell line is unique because of its responsiveness to multiple cytokines and provides a good system for investigating the proliferation and differentiation of myeloid progenitor cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 2 ng/ml recombinant human GM-CSF; fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10(4) viable cells/ml. Do not allow the cell concentration to reach 7 X 10(5) cells/ml.
Interval: Maintain cultures between 3 X 10(4) and 5 X 10(5) viable cells/ml
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 22 hours
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
derivative:ATCC CRL-2451
derivative:ATCC CRL-2512
References: 22415: Kitamura T, et al. IL-1 up-regulates the expression of cytokine receptors on a factor- dependent human hemopoietic cell line, TF-1. Int. Immunol. 3: 571-577, 1991. PubMed: 1832294
22619: Kitamura T, et al. Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood 73: 375-380, 1989. PubMed: 2537111
23007: Kitamura T, et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 140: 323-334, 1989. PubMed: 2663885
23415: Borellini F, Glazer RI. Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1. J. Biol. Chem. 268: 7923-7928, 1993. PubMed: 8463313
30089: Schulte T, et al. Molecular characterization and functional analysis of murine interleukin 4 receptor allotypes. J. Exp. Med. 186: 1419-1429, 1997. PubMed: 9348299
30146: Mueller CG, et al. Polymerase chain reaction selects a novel disintegrin proteinase from CD40-activated germinal center dendritic cells. J. Exp. Med. 186: 655-663, 1997. PubMed: 9271581
30515: Limon A, et al. High-titer retroviral vectors containing the enhanced green fluorescent protein gene for efficient expression in hematopoietic cells. Blood 90: 3316-3321, 1997. PubMed: 9345013
49300: Hu X, et al. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. Cell Growth Differ. 11: 191-200, 2000. PubMed: 10775036
92234: USP Monographs: Sargramostim. Rockville, MD: U.S. Pharmacopeia; USP USP34-NF29, 2011
